Inventor · disambiguated record
Gregory N. Beatch
Also filed as: BEATCH GREGORY N
26 granted patents·29 pending applications·385 citations·filing 1999–2025
96Inventor score
Files withCARDIOME PHARMA CORP29XENON PHARMACEUTICALS INC14UCB FARCHIM SA3BEATCH GREGORY N2FEDIDA DAVID2
Top patents by PatentIndex Score
55 records- 0197US7259184B2Ion channel modulating compounds and uses thereofCARDIOME PHARMA CORP·Filed 2006·Granted Aug 21, 2007·47 cites·25 claims
- 0296US7345087B2Aminocyclohexyl ether compounds and uses thereofCARDIOME PHARMA CORP·Filed 2006·Granted Mar 18, 2008·32 cites·7 claims
- 0394US7057053B2Ion channel modulating compounds and uses thereofCARDIOME PHARMA CORP·Filed 2004·Granted Jun 6, 2006·40 cites·10 claims
- 0493US7524879B2Ion channel modulating compounds and uses thereofCARDIOME PHARMA CORP·Filed 2007·Granted Apr 28, 2009·17 cites·18 claims
- 0593US7053087B1Aminocycloalkyl cinnamide compounds for arrhythmia and analgesics and anestheticsCARDIOME PHARMA CORP·Filed 2000·Granted May 30, 2006·72 cites·6 claims
- 0691US11091441B2Solid state crystalline forms of a selective potassium channel modulatorXENON PHARMACEUTICALS INC·Filed 2020·Granted Aug 17, 2021·4 cites·62 claims
- 0790US7534790B2Ion channel modulating compounds and uses thereofCARDIOME PHARMA CORP·Filed 2007·Granted May 19, 2009·15 cites·11 claims
- 0890US7101877B2Ion channel modulating compounds and uses thereofCARDIOME PHARMA CORP·Filed 2003·Granted Sep 5, 2006·32 cites·11 claims
- 0989US6979685B1Cycloalkyl amine compounds and uses thereofCARDIOME PHARMA CORP·Filed 2000·Granted Dec 27, 2005·32 cites·88 claims
- 1088US8207219B2Ion channel modulating activity IFEDIDA DAVID·Filed 2010·Granted Jun 26, 2012·14 cites·10 claims
- 1187US11135214B2Methods for enhancing the bio availability and exposure of a voltage-gated potassium channel openerXENON PHARMACEUTICALS INC·Filed 2019·Granted Oct 5, 2021·3 cites·26 claims
- 1287US7875611B2Ion channel modulating compounds and uses thereofCARDIOME PHARMA CORP·Filed 2009·Granted Jan 25, 2011·8 cites·11 claims
- 1386US7674820B2Ion channel modulating activity ICARDIOME PHARMA CORP·Filed 2004·Granted Mar 9, 2010·23 cites·8 claims
- 1486US2024316032A1Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel openerXENON PHARMACEUTICAL INC·Filed 2024·Application pending·0 cites
- 1586US2024316033A1Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel openerXENON PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1685US7345086B2Uses of ion channel modulating compoundsCARDIOME PHARMA CORP·Filed 2004·Granted Mar 18, 2008·17 cites·25 claims
- 1783US7507545B2Ion channel modulating activity methodCARDIOME PHARMA CORP·Filed 2004·Granted Mar 24, 2009·12 cites·1 claims
- 1882US8008342B2Ion channel modulating compounds and uses thereofCARDIOME PHARMA CORP·Filed 2009·Granted Aug 30, 2011·5 cites·19 claims
- 1982US2025221980A1Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel openerXENON PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2079US12319657B1Solid state crystalline forms of a selective potassium channel modulatorXENON PHARMACEUTICALS INC·Filed 2025·Granted Jun 3, 2025·0 cites·30 claims
- 2178US7820712B2Uses of ion channel modulating compoundsCARDIOME PHARMA CORP·Filed 2007·Granted Oct 26, 2010·2 cites·11 claims
- 2277US2022062266A1Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel openerXENON PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2376US7105534B2Imidazo[1,2-α]pyridine ether compounds as ion channel modulatorsCARDIOME PHARMA CORP·Filed 2001·Granted Sep 12, 2006·7 cites·29 claims
- 2475US2025275957A1Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel openerXENON PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2575US2024342156A1Methods for treating painXENON PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2675US2024279182A1Solid state crystalline forms of a selective potassium channel modulatorXENON PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2770US2007190156A1Ion channel modulating compounds and uses thereofCARDIOME PHARMA CORP·Filed 2007·Application pending·0 cites
- 2868US2025108044A1Methods of treating depressive disordersXENON PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2966US2022064120A1Solid state forms of a selective potassium channel modulatorXENON PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3066US2014314685A1Ion channel modulating compounds and uses thereofCARDIOME PHARMA CORP·Filed 2013·Application pending·0 cites
- 3164US2013171077A1Ion channel modulating compounds and uses thereofCARDIOME PHARMA CORP·Filed 2012·Application pending·0 cites
- 3263US2016008322A1Ion channel modulating compounds and uses thereofCARDIOME PHARMA CORP·Filed 2015·Application pending·0 cites
- 3363US2009270478A1Ion channel modulating activity iiCARDIOME PHARMA CORP·Filed 2009·Application pending·0 cites
- 3462US2021213009A1Methods of treating painXENON PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3561US2008312309A1Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmiaCARDIOME PHARMA CORP·Filed 2008·Application pending·0 cites
- 3660US12178811B2Methods of treating depressive disordersXENON PHARMACEUTICALS INC·Filed 2020·Granted Dec 31, 2024·0 cites·21 claims
- 3759US2008063707A1Controlled release tablet formulations for the prevention of arrhythmiasCARDIOME PHARMA CORP·Filed 2007·Application pending·0 cites
- 3858US2007004718A1Ion channel modulating compounds and uses thereofCARDIOME PHAMA CORP·Filed 2006·Application pending·0 cites
- 3958US2015099788A1Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmiaCARDIOME PHARMA CORP·Filed 2014·Application pending·0 cites
- 4056US2023405023A1Use of the nav1.6 sodium channel blocker (s)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-n(thiazol-4-yl)benzenesulfonamide, together with strong inducers of cytochrome p450 3a4, in the treatment of conditions associated with navi.6 activityXENON PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4154US2011207730A1Ion channel modulating compounds and uses thereofCARDIOME PHARMA CORP·Filed 2010·Application pending·0 cites
- 4253US8188140B2Uses of ion channel modulating compoundsBEATCH GREGORY N·Filed 2010·Granted May 29, 2012·0 cites·17 claims
- 4353US6939889B2Quarternary ammonium compoundsUCB FARCHIM SA·Filed 2003·Granted Sep 6, 2005·0 cites·16 claims
- 4453US2009041841A1Controlled release tablet formulations for the prevention of arrhythmiasCARDIOME PHARMA CORP·Filed 2008·Application pending·0 cites
- 4552US7687536B2Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anestheticsCARDIOME PHARMA CORP·Filed 2006·Granted Mar 30, 2010·0 cites·4 claims
- 4650US6740673B2Quarternary ammonium compoundsUCB FARCHIM SA·Filed 2002·Granted May 25, 2004·0 cites·2 claims
- 4749US2016089361A1Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmiaCARDIOME PHARMA CORP·Filed 2015·Application pending·0 cites
- 4847US2005197383A1Quaternary ammonium compounds and their use as anti-tussive agentsUCB FARCHIM SA·Filed 2005·Application pending·0 cites
- 4945US2007197632A1Aminocyclohexyl ether compounds and uses thereofCARDIOME PHARMA CORP·Filed 2005·Application pending·0 cites
- 5042US2003181489A1Quaternary ammonium and their use as anti-tussive agentFiled 2000·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →